Vortioxetine; Placebo
Проводит Takeda
Страница компанииA Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00744627/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 301 чел. во всех странах исследования.
- Плановая дата окончания (07.2009) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 37
Критерии включения
- Suffers from a primary diagnosis of Generalized Anxiety Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.
- Has a Hamilton Anxiety Scale total score ≥20 at Screening and Baseline.
- Has a Hamilton Anxiety Scale score ≥2 on both Item 1 (anxious mood) and Item 2 (tension) at Screening and Baseline.
- Has a Montgomery-Åsberg Depression Rating Scale total score ≤16 at Screening and Baseline.
- Male and females of childbearing potential who are sexually active agree to use adequate contraception from Screening throughout the duration of the study and for 1 month after the last dose of study medication.
Критерии невключения
- Has received any investigational compound <30 days before Screening or 5 half-lives prior to Screening.
- Has received Lu AA21004 in a previous clinical study or as a therapeutic agent.
- Has 1 or more of the following:
- Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the DSM-IV-TR.
- Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
- Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
- Presence or history of a clinically significant neurological disorder (including epilepsy).
- Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington disease, etc).
- Any Axis II disorder that might compromise the study.
- Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study including:
- Nonsteroidal anti-inflammatory drugs
- Rifampin
- Macrolide antibiotics
- Hormones
- Hypoglycemic agents and Insulin
- Systemic steroids
- Antineoplastics
- Antiobesity agents
- Antidiarrheal agents (episodic use allowed)
- Antifungal agents (episodic topical use allowed)
- Antihistamines (episodic use of loratadine, desloratadine, cetirizine allowed)
- Cough/cold agents (episodic use allowed but preparations containing pseudoephedrine and narcotics are NOT allowed)
- Diuretics (episodic use allowed)
- Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
- Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
- Has received electroconvulsive therapy within 6 months prior to Screening.
- Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
- Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
- Has an alanine aminotransferase, aspartate aminotransferase or bilirubin level >1.5 times the upper limits of normal.
- Has a serum creatinine of >1.5 times the upper limits of normal.
- Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.
- Has clinically significant abnormal vital signs as determined by the investigator.
- Has 1 or more laboratory values outside the normal range, based on the blood or urine samples taken at Screening, that are considered by the investigator to be clinically significant.
- Has thyroid stimulating hormone value outside the normal range at Screening and is deemed clinically significant by the investigator.
- Has an abnormal electrocardiogram as determined by the central reader and confirmed as clinically significant by the investigator.
- Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
- Has previously participated in this study.
Источник: ClinicalTrials.gov, NCT00744627 · запись обновлена в реестре 3 марта 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 24
- Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 — Baseline to Week 8
Цель исследования
The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00744627 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.